This review explores using nanotechnology to enhance the delivery of neuroprotective phytochemicals from medicinal plants for Alzheimer's disease (AD), addressing issues of bioavailability, solubility, and blood-brain barrier penetration, and highlights the potential of nanocarriers to revolutionize neuroprotective drug delivery and improve patient outcomes.

This study developed a novel mouse model with tamoxifen-inducible knockout of the Gnpat gene, enabling late-onset plasmalogen deficiency to investigate its role in Alzheimer's disease. The model exhibited significant plasmalogen reduction and associated behavioral and nerve function changes, providing a valuable tool for future research on plasmalogen involvement in neurodegeneration and potential therapies.